Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Accumulated Expenses: 2013-2025

Historic Accumulated Expenses for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $13.4 million.

  • Coherus Oncology's Accumulated Expenses fell 78.04% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 78.04%. This contributed to the annual value of $60.3 million for FY2024, which is 42.79% down from last year.
  • Coherus Oncology's Accumulated Expenses amounted to $13.4 million in Q3 2025, which was down 5.60% from $14.2 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Accumulated Expenses ranged from a high of $115.7 million in Q1 2024 and a low of $13.4 million during Q3 2025.
  • For the 3-year period, Coherus Oncology's Accumulated Expenses averaged around $56.2 million, with its median value being $60.3 million (2024).
  • As far as peak fluctuations go, Coherus Oncology's Accumulated Expenses spiked by 260.94% in 2024, and later tumbled by 78.04% in 2025.
  • Quarterly analysis of 5 years shows Coherus Oncology's Accumulated Expenses stood at $48.1 million in 2021, then rose by 4.09% to $50.1 million in 2022, then spiked by 110.36% to $105.4 million in 2023, then tumbled by 42.79% to $60.3 million in 2024, then slumped by 78.04% to $13.4 million in 2025.
  • Its Accumulated Expenses stands at $13.4 million for Q3 2025, versus $14.2 million for Q2 2025 and $46.3 million for Q1 2025.